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KinaseThe ER–Golgi intermediate compartment (ERGIC) is an organelle through which cargo proteins pass and are
being transferred by either anterograde or retrograde transport between the endoplasmic reticulum (ER) and
the Golgi apparatus. We examined the effect of 80 different kinase inhibitors on ERGIC morphology and found
that rottlerin, a PKCδ inhibitor, induced the dispersion of the perinuclear ERGIC into punctate structures. Rottlerin
also delayed anterograde transport of vesicular stomatitis virus G protein (VSVG) from the ER to the Golgi and
retrograde transport of cholera toxin from cell surface to the ER via the Golgi. RNA interference revealed that
knockdown of PKCδ or ε resulted in the dispersion of the ERGIC, but unexpectedly did not inhibit VSVG and chol-
era toxin transport. We also found that rottlerin depolarized the mitochondrial membrane potential, as does
carbonylcyanide-p-triﬂuoromethoxyphenylhydrazone (FCCP), an uncoupler, and demonstrated that a decrease
in the intracellular adenosine triphosphate (ATP) levels by rottlerinmight underlie the block in transports. These
results suggest that PKCδ and ε speciﬁcally regulate the morphology of the ERGIC and that the maintenance of
ERGIC structure is not necessarily required for anterograde and retrograde transports.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The endoplasmic reticulum (ER) and the Golgi complex exchange
proteins and lipids by vesicular transport. The balance between antero-
grade (ER-to-Golgi) and retrograde (Golgi-to-ER) transports between
the two organelles is tightly regulated. The ER–Golgi intermediate
compartment (ERGIC), also known as vesicular tubular clusters (VTC),
is a membranous structure located between the ER and the Golgi. The
ERGIC compartment has both a perinuclear localization near the cis-
Golgi complex as well as a punctate cytoplasmic localization near ER
exit sites.
As expected from its localization between the ER and the Golgi, the
ERGIC is involved in anterograde and retrograde protein trafﬁcking. In
fact, several proteins localized to the ERGIC play roles in membrane traf-
ﬁcking. For example, the mannose-speciﬁc membrane lectin ERGIC53, artment; ER, endoplasmic retic-
cholera toxin B subunit; PMA,
de-p-triﬂuoromethoxyphenyl-
r; endo-H, endoglycosidase-H.
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urata).
rights reserved.deﬁnitivemarker of the ERGIC, acts as a receptor for speciﬁc glycoprotein
cargoes such as coagulation factors V andVIII [1,2], alpha1-antitrypsin [3],
cathepsin C [4,5], and cathepsin Z [6], to facilitate their transport from the
ER to the ERGIC. Another ERGIC-localized protein, multiple coagulation
factor deﬁciency protein 2 (MCFD2), is required for the efﬁcient secretion
of coagulation factors V and VIII [7]. We also demonstrated previously
that Yip1A (YIPF5), a member of the Yip family, localizes to the ERGIC
and is involved in COP I-independent retrograde transport by regulating
membrane recruitment of Rab6 [8].
An important question is how ERGIC functions in bidirectional
transport. Fluorescence microscopy using cells expressing Green
Fluorescent Protein (GFP) fused to a temperature-sensitive mutant
of VSVG has revealed the direct movement of the ERGIC from the
ER toward the Golgi along microtubules [9,10]. These results
suggested that the ERGIC acts as a carrier that migrates towards and
fuses with the cis-Golgi to deliver cargo proteins. On the other hand,
other researchers have suggested that the ERGIC may instead be a sta-
tionary membrane complex, where vesicles form for transporting
cargo proteins to different organelles. This notion was supported by
the ﬁnding that β-COP, a component of COPI vesicles, localizes to
the ERGIC [11], and that COPI-dependent vesicles could be formed
from the ERGIC membrane in a manner dependent upon Rab2,
GAPDH and PKCι [12]. Although COPI vesicles are known to play a
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it remains to be determined whether ERGIC-derived COPI vesicles
recycle their cargo back to the ER, deliver them to the Golgi, or both.
Organelles change their morphology in response to various physio-
logical conditions and to the balance between incoming and outgoing
transports of proteins. The regulatory mechanisms governing the
morphology of the Golgi apparatus have been studied extensively. The
Golgi apparatus comprises stacked cisternae in the perinuclear region
during interphase, but is dispersed throughout the cytoplasm as small
vesicles [15,16], or is distributed to the ER duringmitosis [17]. Thismitot-
ic disruption of Golgi morphology is regulated by the kinases, Cdc2 [18],
mitogen-activated protein kinase (MEK) 1 [19], or both [20]. Lowe et al.
[21] demonstrated that Cdc2 phosphorylates GM130, a tightly associated
peripheral membrane protein localized to the cis-Golgi, and that the
phosphorylation of GM130 inhibits its binding to the vesicle-docking
protein, p115, leading to a block in vesicle fusion with the Golgi mem-
brane. Feinstein and Linstedt [19,22] showed thatMEK-dependent phos-
phorylation of GRASP55, another Golgi-associated peripheral membrane
protein, caused Golgi unlinking at the onset of mitosis, which facilitates
cell-cycle progression. Furthermore, Golgi components were absorbed
into the ER when anterograde transport from the ER to the Golgi was
inhibited by brefeldin A treatment or forced expression of dominant-
negative Sar1 protein [23]. Although the morphology of the ERGIC is
also dependent upon the stage of the cell cycle or vesicular transport,
the precise regulatory mechanisms controlling its morphology remain
to be determined.
siRNA or inhibitor screening of the kinome is a powerful method to
identify novel regulatory mechanisms of various biological processes.
Previously, we identiﬁed ﬁve kinases that regulate cation-independent
mannose-6-phosphate receptor (CI-MPR) transport by examining the
effect of kinase inhibitors and a kinase siRNA library on trafﬁcking path-
ways of the CI-MPR between endosomes and the Golgi apparatus [24].
Furthermore,we determined that GSK3β, one of the 5 identiﬁed kinases,
guided exocytic transport at the trans-Golgi network by modulating the
phosphorylation state of CLASP2 and thereby the afﬁnity of the latter for
microtubules [25]. In this study, we examined the effect of 80 kinase
inhibitors on the organization of the ERGIC. We found that rottlerin, a
PKCδ inhibitor, induced dispersion of perinuclear ERGIC (n-ERGIC) to
cytoplasmic punctate structures and inhibited anterograde transport of
VSVG and retrograde transport of cholera toxin. We also demonstrated
speciﬁc roles for PKCδ and ε in the changes in ERGIC morphology, but
not in the block in VSVG and cholera toxin transports.
2. Materials and methods
2.1. Cell culture
HeLa cells were cultured in DMEM supplemented with 10% FCS
and penicillin/streptomycin (Gibco).
2.2. Reagents and antibodies
Rottlerin and FCCP were obtained from Calbiochem. PMA was
obtained from Sigma. TMRMwas purchased from Invitrogen. The follow-
ing antibodies were used: mouse monoclonal anti-ERGIC53 antibody
(clone G1/93; Alexis), rabbit monoclonal anti-GM130 (clone EP892Y;
abcam), rabbit polyclonal anti-GFP (598; MBL), mouse monoclonal
anti-GAPDH (clone 6C5; Millipore), rabbit monoclonal anti-PKCδ (clone
EP1484Y; abcam), rabbit polyclonal anti-phospho-PKCδ (Thr505)
(9374; Cell signaling), mouse anti-PKCε (BD Transduction Laboratories),
rabbit polyclonal anti-Rab2 (96509; abcam) antibodies. The rabbit poly-
clonal antibody against Yip1A, B8460, was raised as described in [8].
The following secondary antibodies were used for immunoﬂuorescence:
Cy2-conjugated anti-mouse (Chemicon) and Cy3-conjugated anti-rabbit
antibodies (Chemicon). The following secondary antibodies were usedfor Western blot: horse radish peroxidase (HRP)-conjugated anti-
mouse (Promega) and anti-rabbit antibodies (Chemicon).
2.3. Plasmid
The GFP-VSVGts045 construction was a gift from Dr. Jennifer
Lippincott-Schwartz (National Institute of Health, Bethesda, MD). To
synthesize the Sec61α1-GFP construct, cDNA encoding the amino
acid of Sec61α1 was ampliﬁed by PCR from human cDNA library.
The PCR fragment was inserted into upstream of EGFP cDNA in
pEGFP-N1 vector (Clontech).
2.4. Plasmid and siRNA transfection
For plasmid transfection, cells were transfected using Lipofectamine
LTX reagent (Invitrogen) according to the manufacturer's instructions.
Validated or pre-designed siRNA oligonucleotides that targeted
human PKCδ (ID: S11099) and PKCε (ID: 679) were purchased from
Ambion. For gene silencing of HeLa cells by siRNA transfection, cells
were transfected with 50 μM siRNA using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer's instructions.
2.5. Immunoﬂuorescence microscopy
For staining of ERGIC53 and GM130, cells were permeabilized and
ﬁxed with methanol:acetone [1:1 (vol/vol)] at 4 °C for 6.5 min and
then blocked with PBS containing 5% skim milk. After blocking cells
were incubated with primary antibodies for 2 h and subsequently
with ﬂuorescence-conjugated secondary antibodies for 1 h. The sam-
ples were viewed with a 63×Plan-NEOFLUAR oil immersion objective
on a confocal microscope, LSM 510 (Carl Zeiss, Jena, Germany). For
quantiﬁcation of the morphological change of n-ERGIC/cis-Golgi in the
cells, we counted the cells inwhich the n-ERGIC/cis-Golgi had dispersed
by more than 10 or 20 μm.
2.6. Assay to measure the anterograde transport of GFP-VSVGts045
The plasmid encoding GFP-VSVGts045was transfected into the cells.
The cells were incubated at 39 °C for 24 h to allow the accumulation of
the VSVG protein within the ER, and subsequently incubated at 32 °C
for the indicated times to induce the transport of VSVG from the ER.
The cells were divided into three classes upon examination under the
microscope. The ﬁrst class comprised cells in which GFP-VSVGts045
was present only in the ER network, i.e. the VSVG was localized to a
reticular network throughout the cytoplasm; the second corresponded
to cells in which VSVG accumulated in the juxtanuclear structures;
and the third, cells in which VSVG appeared at ﬁlopodia or lamellipodia.
The number of cells in each class was counted. Cells in which GFP-
VSVGts045 was present in both the ER and Golgi were assigned to the
second class. Then, we calculated the percentage of cells in which GFP-
VSVGts045 was localized to the ER, the Golgi or the plasma membrane.
For all experiments, three independent transport assays were
performed, and the means and standard deviations were plotted. In
the biochemical assay with endo-H, cells expressing GFP-VSVGts045
protein were transferred from 39 °C to 32 °C to induce the transport
VSVG from ER, and then incubated for the indicated times. The cells
were lysed and incubated with endo-H according to the manufacturer's
instructions (New England Biolabs). The deglycosylated proteins were
separated by SDS-PAGE, and subjected to Western blot analysis using
anti-GFP and anti-GAPDH antibodies.
2.7. Assay to measure the retrograde transport of Cholera toxin B subunit
(CtxB)
Alexa ﬂuor 488 or 594-labeled Cholera toxin B subunit (CtxB) was
obtained from Molecular Probes. HeLa cells treated with DMSO or
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incubated with 1 μg/ml CtxB on ice for 30 min. After washing twice
with PBS, the cells were incubated with pre-warmed medium for
the indicated times. The cells were ﬁxed and observed using a confo-
cal microscope. We deﬁned the cells in which CtxB had accumulated
in juxtanuclear structures as containing CtxB in the Golgi, cells that
showed the clear appearance of the toxin in the nuclear envelope
and cytoplasmic reticular structures as containing CtxB in the ER,
and cells in which CtxB was present at ﬁlopodia or lamellipodia as
containing the toxin at the plasma membrane. We counted the num-
ber of cells in these locations. For all experiments, three independent
transport assays were performed, and the percentage of cells in which
CtxB was in the Golgi, the ER or plasma membrane is shown.
2.8. Flow cytometry
HeLa cells were treated with 6 μM rottlerin or 10 μM FCCP for
90 min. The cells were washed twice with PBS and incubated with
pre-warmed DMEM containing 30 nM TMRM. The cells washed
with PBS were trypsinized, resuspended, and subjected to ﬂow
cytometry using a Guava easyCyte 8HT ﬂow cytometry system
(Millipore).
2.9. Automatic morphometric analysis for siRNA-treated cells
(AUTOMORPH(Si))
Image analysis method is proceeded in the following two steps.
Firstly, we made the algorithm which detects cell regions from the
original images. In the original image (Supplementary Fig. S3Aa),
we drew cell region example as detection area (Supplementary Fig.
S3Ab: green ROI) and suppression region (Supplementary Fig. S3Ab:
red ROI) and background region (Supplementary Fig. S3Ab: yellow
ROI). CL-Quant analyzed ROI information and automatically made
the algorithm which create segmentation masks at the cell region
(Supplementary Fig. S3Ac). Quantitative analysis value of segmentation
masks is also calculated automatically. Secondly, wemade the algorithm
which decides the effect of drug as positive or negative. We prepared
positive control images from AG1478-treated cells (Supplementary Fig.
S3B, AG1478) and rottlerin-treated cells (Supplementary Fig. S3B, Rot-
tlerin), and negative control images from GW5074-treated cells
(Supplementary Fig. S3B, GW5074) as teaching truth for decision.
Using step1 algorithm, these control images were analyzed. Detected
segmentation masks of cells were taught one by one as positive truth
or negative truth. Total 64 cells were used as truth (Supplementary Fig.
S3). CL-Quant analyzed quantitative value of segmentation masks both
positive truth and negative truth, and automatically found the optimum
decision tree algorithm (Supplementary Fig. S4).
2.10. Electron microscopy
For conventional microscopic observation, HeLa cells, grown on
the low-ﬂuorescence plastic ﬁlms (LF1, Sumitomo Bakelite; MS-
92132), were treated with 6 μM rottlerin for 90 min and ﬁxed with
2.5% glutaraldehyde (Electron Microscopy Sciences) in 0.1 M sodium
phosphate buffer, pH 7.4 (PB) for 2 h at room temperature. The cells
were washed with the buffer, and were post-ﬁxed in PB containing
1% OsO4 and 1.5% potassium ferrocyanide for 60 min at room temper-
ature, and washed with distilled water. The cells were dehydrated in
a series of graded ethanol solutions and embedded in epoxy resin.
Ultra-thin sections were doubly stained with uranyl acetate and
lead citrate and observed under an H7600 electron microscope
(Hitachi).
For immuno-electron microscopic observation, cells were ana-
lyzed by immunoelectron microscopy by using a pre-embedding
gold enhancement method with a slight modiﬁcation [26]. Control
or PKCδ-knockdown cells were grown on the low-ﬂuorescence plasticﬁlms, LF1, and transfected with GFP-VSVGts045 plasmid. After 24 h
incubation at 39 °C, the cells were treated with 50 μM cycloheximide
for 30 min to stop protein synthesis, and transferred from 39 °C to
15 °C and incubated for 2 h to allow GFP-VSVGts045 to accumulate
in the ERGIC. Then the cells were ﬁxed with 4% paraformaldehyde
(Nacalai Tesque; 26126–54) in PB for 2 h at room temperature and
washed with the buffer. The cells were permeabilized in PB contain-
ing 0.25% saponin for 30 min, and then blocked in PB containing
0.1% saponin, 10% bovine serum albumin, 10% normal goat serum,
and 0.1% cold water ﬁsh skin gelatin (blocking solution) for 30 min.
The cells were exposed to rabbit anti-GFP serum (500× diluted) in
blocking solution overnight, and then they were incubated with the
Fab′ fragment of a goat anti-rabbit IgG conjugated to colloidal gold
(1.4 nm in diameter) in blocking solution for 2 h. The cells were
ﬁxed with 1% glutaraldehyde in PB for 10 min. The gold labeling
was intensiﬁed with a gold enhancement kit (GoldEnhance-EM;
Nanoprobes) for 2 min according to the manufacturer's protocol.
After washing, the cells were postﬁxed in PB containing 1% OsO4
and 1.5% potassium ferrocyanide for 60 min, dehydrated in a series
of graded ethanol solution, and embedded in epoxy resin. Ultrathin
sections were cut horizontally to the cell layer and observed under
a Hitachi H7600 electron microscope.
2.11. Luciferin/luciferase assay
We quantiﬁed the intracellular ATP in cells treated rottlerin or
FCCP using ATP determination kit (Molecular probes®; A22066)
according to the manufacturer's instructions.
2.12. Statistical analysis
Data analysis was carried out using Student's t-test. Experiments
were performed at least three times. Values were expressed as the
mean±standard deviation and data were considered signiﬁcant at
*Pb0.05, **Pb0.005, ***Pb0.0005, N.S. P>0.05.
3. Results
3.1. Rottlerin induces the dispersion of the n-ERGIC/cis-Golgi
To determine the types of kinase that affect the morphology of the
n-ERGIC/cis-Golgi, we examined the effect of 80 different kinase in-
hibitors on the localization of ERGIC53 and GM130 using our cell
array chip-based automatic screening system [24]. HeLa cells were
ﬁrst incubated with various kinase inhibitors at a concentration of
10 or 100 μM at 37 °C for 90 min, and then ﬁxed and immunostained
with antibodies against ERGIC53, a marker of the ERGIC, and GM130,
a marker of the cis-Golgi. Images were acquired using the INCell Ana-
lyzer 1000 or LSM510 confocal microscope, and the colocalization of
perinuclear ERGIC53 ﬂuorescence (green) and GM130 ﬂuorescence
(red) was analyzed. In control cells (Fig. 1A, DMSO), ERGIC53 ﬂuores-
cence was observed mainly within the perinuclear region, and was
partially colocalized with GM130. A subfraction of the ERGIC53 signal
was observed scattered throughout the cytoplasm in punctate
structures.
We identiﬁed two kinase inhibitors that disrupt the localization of
ERGIC53 and GM130: rottlerin and AG1478. Rottlerin is an inhibitor of
PKCδ, and AG1478 inhibits EGFR (epidermal growth factor receptor)
kinase. When HeLa cells were treated with these kinase inhibitors,
both perinuclear ERGIC53 and GM130 became localized to punctate cy-
toplasmic structures (Fig. 1A, rottlerin). Since the effect of AG1478 on
ERGIC structures has been reported elsewhere [27], we focused here
on the effects of rottlerin. To quantify the morphological changes of
ERGIC53, we calculated the percentage of cells that exhibited dispersion
of the n-ERGIC into punctate cytoplasmic structures (Fig. 1B).We found
that ~80% of rottlerin-treated cells exhibited dispersion of the n-ERGIC/
A B
Fig. 1. Rottlerin induces the disruption of the n-ERGIC/cis-Golgi. (A) HeLa cells were treated with DMSO or 20 μM rottlerin for 90 min. The cells were immunostained with anti-
ERGIC53 and anti-GM130 antibodies. ERGIC53 and GM130 were observed as dotted structures within the cytoplasm of rottlerin-treated cells. Scale bars: 10 μm. (B) To quantify
the dispersion, we measured the diameter of the area, where n-ERGIC/cis-Golgi was dispersed in the cytoplasm, and calculated the average percentage (±s.d.) of cells, in which
the n-ERGIC/cis-Golgi was dispersed by more than 10 or 20 μm (graph). Unlike the limited disassembly ofmedial-/trans-Golgi between 10 and 20 μm in the perinuclear region (Sup-
plementary Fig. S1), n-ERGIC/cis-Golgi was fragmented throughout cytoplasm. Values represent the means±s.d.; n=100, *Pb0.05, **Pb0.005 (Student's t-test).
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type (Fig. 1B). We observed that the medial-/trans-Golgi was disas-
sembled just around the perinuclear region by rottlerin treatment (for
details, see the legend of Supplementary Fig. S1A). However, a conven-
tional EM analysis revealed that the stacks of cisternae were clearly
observed in rottlerin-treated cells (Supplementary Fig. S1B). So we
concluded that the maintenance of the Golgi organization in rottlerin-
treated cells was almost intact.
3.2. Rottlerin delays anterograde transport of VSVG and retrograde
transport of CtxB
The ERGIC is reported to play a role in both anterograde and retro-
grade transports between the ER and the Golgi [6,28–32]. Having
found that rottlerin induced the disruption of the n-ERGIC, we assayed
the anterograde transport of VSVG from the ER to the plasma mem-
brane via the Golgi, and the retrograde transport of the CtxB from the
plasma membrane to the ER via the Golgi in rottlerin-treated cells.
Since the transport assaywas based on the localization of cargo proteins
to organelles (morphometric assay), the disruption of n-ERGIC/cis-
Golgi in 20 μM rottlerin-treated cells made these measurements difﬁ-
cult. Therefore, we identiﬁed a concentration of rottlerin that produced
a less profound disruption of ERGIC morphology, and we found that
6 μM was sufﬁcient. HeLa cells were treated with DMSO, 2.5 μM, 6 μM,
or 20 μM rottlerin for 90 min, and then were immunostained with anti-
bodies against ERGIC53 and GM130.We counted the number of cells, in
which the n-ERGIC/cis-Golgi was dispersed by >~10 μm.We found that
~20%, 42%, 61%, and 80% of cells exhibited dispersion of the ERGIC
following exposure to DMSO, 2.5 μM, 6 μM, and 20 μM rottlerin, respec-
tively (data not shown). Since 6 μM rottlerin caused the dispersion of
ERGIC structures in more than half of cells, coupled with the fact that
this concentration was frequently used in others studies [33,34], we
chose to perform the transport assay using 6 μM rottlerin.
The kinetics of VSVG transport from the ER to theGolgiwasmeasured
in DMSO- or rottlerin-treated cells as described in Kano et al. [8]. Plasmid
encoding GFP-VSVGts045 was transfected into HeLa cells. After incuba-
tion for 24 h at 39 °C to allow accumulation of VSVG at the ER, the cells
were treated with 6 μM rottlerin or DMSO at 39 °C for 90 min, and then
were shifted to 32 °C to initiate ER export of VSVG protein. The extent
of VSVG transport at each incubation time was estimated by morpho-
metric analysis (Fig. 2A). 15 min after release from temperature block
by shifting to 32 °C, VSVG had accumulated at the Golgi in ~90% of the
control cells (Fig. 2B DMSO, 15 min and 2C), whereas the percentage of
cells with Golgi-accumulated VSVGwas decreased to less than 10% in re-
sponse to treatment with rottlerin (Fig. 2B, Rottlerin, 15 min and 2C). In
addition, most of the Golgi-accumulated VSVG could be transported tothe plasma membrane within 30 min after arrival at the Golgi in control
cells (Fig. 2B DMSO, 60 min and 2C DMSO, 30–60 min), whereas it was
delayed in rottlerin-treated cells (Fig. 2B rottlerin, 60 min and 2C Rottle-
rin, 60–90 min), indicating that VSVG transport from the Golgi to the
plasma membrane was also inhibited by rottlerin. The inhibitory effect
of rottlerin on VSVG transport was also conﬁrmed by analysis of its resis-
tance to endoglycosidase-H (endo-H) activity. As shown in Fig. 2D, the
resistance of VSVG to endo-H was delayed by treatment of cells with
rottlerin.
We next investigated the transport of CtxB from the plasma
membrane to the ER in DMSO- or rottlerin-treated cells bymorphomet-
ric analysis. HeLa cells were treated with DMSO or 6 μM rottlerin for
90 min, and CtxB was bound to the cell surface on ice and incubated
with DMEM containing 10% FCS with or without 6 μM rottlerin for indi-
cated time (Fig. 2F and G). Rottlerin treatment had no effect on the
amount of CtxB bound to the cell surface (data not shown). We found
that rottlerin delayed the retrograde transport of CtxB from the endo-
some to the ER via the Golgi. The percentage of cells in which CtxB
had accumulated at the Golgi in rottlerin-treated cells at 30 min was
45% compared to 82% in the control cells (Fig. 2G). Furthermore, CtxB
arrived at the ER in 6 h in 86% or 44% of DMSO- or rottlerin-treated
cells (Fig. 2F 6h and 2G). These results suggest that rottlerin treatment
could lead to a delay in both anterograde transport of VSVG and retro-
grade transport of CtxB.
To support the transport assays usingmorphometric analysis (Fig. 2C
and E) and the biochemical analysis (Fig. 2D), we quantiﬁed the coloca-
lization of VSVG with p230, a trans-Golgi marker, and that of CtxB with
Sec61α1-GFP, an ERmarker in control and rottlerin-treated cells. For the
analysis of anterograde transport, HeLa cells were ﬁrst transfected with
plasmid encoding GFP-VSVGts045 and incubated at 39 °C for 24 h. The
cells were treated with 6 μM rottlerin or vehicle alone at 39 °C for
90 min, and then were transferred to 32 °C for 15 min. The cells were
ﬁxed and were stained with antibody against p230. The number of
cells in which VSVG colocalized with p230 was 45% (n=33) in control
cells, which dropped to 17% (n=32) in rottlerin-treated cells (Supple-
mentary Fig. S2A). For the analysis of retrograde transport, HeLa cells
were transfected with plasmid encoding Sec61α1-GFP. The cells were
treated with 6 μM rottlerin or vehicle alone for 90 min. After washing
with PBS, Alexa594-conjugated CtxB was bound to the plasma mem-
brane on ice, and was internalized by incubation at 37 °C for 6 h in the
presence of rottlerin (see Materials and methods). We found that 53%
or 26% of cells showed colocalization of CtxB with Sec61 α1-GFP in
control or rottlerin-treated cells, respectively (n=51 or 31). These
results strengthen our results that rottlerin delayed the anterograde
transport of VSVG and the retrograde transport of CtxB (Supplementary
Fig. S2C).
AC
D
E
G
F
B
Fig. 2. Transport assay for VSVG and CtxB in rottlerin-treated cells. (A) Representative image of the cells, in which GFP-VSVGts045 was localized to the ER, to the Golgi or to the
plasma membrane (PM). Scale bars: 10 μm. (B) Representative images of GFP-VSVGts045 expressing cells with DMSO or rottlerin treatment. HeLa cells were transfected with
GFP-VSVGts045 plasmid and incubated at 39 °C for 24 h. The cells were treated with 6 μM rottlerin at 39 °C for 90 min, then were further incubated at 32 °C for 15 or 60 min.
Scale bars: 10 μm. (C) Kinetics of GFP-VSVGts045 transport in DMSO or rottlerin-treated cells. The graph shows the mean percentage of the cells (±s.d.), in which GFP-
VSVGts045 was localized to the ER, to the Golgi or to the plasma membrane (PM) n=100. (D) Biochemical transport assay for GFP-VSVGts045 using endo-H. HeLa cells were trans-
fected with GFP-VSVGts045 plasmid and incubated at 39 °C for 24 h. Then the cells were treated with DMSO or 6 μM rottlerin for 90 min, and transferred from 39 °C to 32 °C to
induce the transport of VSVG from the ER, and incubated for the indicated times. The cells were then lysed and incubated with endo-H. The proteins were separated by SDS-
PAGE and subjected to Western blot analysis using anti-GFP and anti-GAPDH antibodies. (E) Representative image of cells, in which CtxB was localized to the plasma membrane
(PM), to the Golgi or to the ER. Scale bars: 10 μm. (F) Representative images of cells infected with CtxB, which were treated with DMSO or rottlerin. CtxB were bound to the cell
surface and the cells were incubated at 37 °C for 0.5 h or 6 h in the presence of DMSO or 6 μM rottlerin. (G) Kinetics of CtxB transport in DMSO or rottlerin-treated cells. The
graph shows the mean percentage of cells (±s.d.), in which CtxB was localized to the plasma membrane (PM), to the Golgi or to the ER n=100.
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[35]. So we performed Western blot analysis using an antibody that
speciﬁcally recognizes PKCδ phosphorylated at Thr505 so as to deter-
mine whether rottlerin actually inhibited this activity. Unexpectedly,
exposure of cells to rottlerin decreased PKCδ activity to only 76% of
the control value (Supplementary Fig. S2D, E, Rottlerin), although
the rottlerin treatment caused the perturbation of the transports of
VSVG and CtxB. This result suggested the possibility that the
rottlerin-mediated decrease in PKCδ activity might not necessarily
be correlated with its phosphorylation status at Thr505 (see
Discussion).
3.3. PMA, an activator of PKC, restores rottlerin-induced dispersion of the
n-ERGIC/cis-Golgi, but not the delay of anterograde and retrograde
transports
Having found that rottlerin induced changes in the morphology of
the n-ERGIC/cis-Golgi and inhibition of anterograde and retrograde
transports of VSVG and CtxB, we next investigated the effect of phorbol
12-myristate 13-acetate (PMA), an activator of PKC, on the n-ERGIC/cis-
Golgi structures and vesicular transport in rottlerin-treated cells. HeLa
cells were ﬁrst incubated with 20 μM rottlerin at 37 °C for 90 min,
followed by 200 nM PMA at 37 °C for 60 min. The cells were ﬁxed and
stained with antibodies against ERGIC53 and GM130. As shown in
Fig. 3A (rottlerin+PMA), the rottlerin-induced dispersion of the n-
ERGIC/cis-Golgi was inhibited by PMA. We conﬁrmed PMA-treatment
had no effect on the morphology of n-ERGIC/cis-Golgi (Fig. 3A PMA).
We measured the extent of dispersion by morphometric analysis as
described in Fig. 1B, and found that the percentage of cells that con-
tained a dispersed n-ERGIC/cis-Golgi was decreased from ~56% in cells
treated with rottlerin to ~27% in response to the subsequent treatment
with PMA (Fig. 3B).
We next tested whether PMA could restore the inhibition of anter-
ograde transport of VSVG by rottlerin. Plasmid encoding GFP-
VSVGts045 was transfected into HeLa cells. After 24 h at 39 °C, the
cells were incubated with DMSO or 6 μM rottlerin at 39 °C for
90 min, then further with DMSO or 200 nM PMA at 39 °C for
60 min. Sixty min after shifting the temperature to 32 °C, the cells
were ﬁxed and the percentage of cells in which GFP-VSVGts045 had
been transported to the plasma membrane was calculated. Unexpect-
edly, as shown in Fig. 3C, the anterograde transport of VSVG was
inhibited in cells treated with rottlerin alone (42%) to an extent sim-
ilar to that observed in cells treated with both rottlerin and PMA
(49%).
We also investigated whether PMA could restore the rottlerin-
induced delay of CtxB transport (Fig. 3D). HeLa cells were treated with
DMSO, 6 μM rottlerin, 6 μM rottlerin and 200 nM PMA, or 200 nM PMA
for 90 min. After washing with PBS, Alexa488-conjugated CtxB was
bound to the plasmamembrane on ice, and was internalized by incuba-
tion at 37 °C for 6 h in the presence of rottlerin.We found that CtxB was
transported to the ER in 63% of control cells but in 24% or 35% of cells
treated with rottlerin alone or both rottlerin and PMA, respectively. In
addition, we conﬁrmed that PMA alone had no effect on the retrograde
transport of CtxB (Fig. 3D PMA). These results suggest that members of
the PKC family, probably PKCδ, are involved in rottlerin-dependent
changes in n-ERGIC/cis-Golgi morphology, but not in rottlerin-
dependent delay in both anterograde transport of VSVG and retrograde
transport of CtxB via the Golgi apparatus.
3.4. PKCδ knockdown causes the dispersion of n-ERGIC/cis-Golgi
morphology
Rottlerin has been used as a protein kinase Cδ (PKCδ)-selective
inhibitor, although its speciﬁcity has been recently questioned [36].
Therefore, we performed RNA interference (RNAi) to examine the effect
of PKCδ on the morphology of the n-ERGIC/cis-Golgi. A siRNA targetedto human PKCδ was transfected into HeLa cells, and after 72 h incuba-
tion, the cells were immunostained with antibodies against ERGIC53
and GM130 (Fig. 4A). We showed by Western blot analysis that the
amount of PKCδ protein was reduced to approximately 20% of the
normal level by gene silencing of PKCδ (Fig. 4B). Knockdown of PKCδ in-
duced the redistribution of the n-ERGIC/cis-Golgi to cytoplasmic punc-
tate structures, as was observed following treatment with rottlerin.
We performed morphometric analysis in HeLa cells transfected with
either the PKCδ siRNA or a scrambled control thereof as described
above. We found that the dispersion of the n-ERGIC/cis-Golgi was
detected in ~50% of the PKCδ knockdown cells, compared to only ~25%
of the scrambled control cells (Fig. 4C). In contrast, the morphology of
the peripheral ERGIC was unchanged in PKCδ-knockdown cells.
We found that the percentage of cells that contained a dispersed n-
ERGIC was ~80% in rottlerin-treated cells (Fig. 1B), but was ~50% in
PKCδ knockdown cells (Fig. 4C). The decrease in the percentage of
cells with a dispersed ERGIC might be due to the inefﬁcient suppression
of PKCδ expression by RNAi. Compared to the broad acting of inhibitors
to cells, the partial knockdown by siRNA transfection should require
more quantitative and more objective analysis. To conﬁrm our decision
that PKCδ knockdown substantially disrupted the n-ERGIC/cis-Golgi
morphology, we have developed an image analysis method, which can
decide automatically the effect of siRNA to all cells in images based on
the ﬁxed criterion (see in detail in Materials and methods), using
image analysis software CL-Quant (Nikon Corporation). We call the
analysis method AUTOMORPH(si) (automatic morphometric analysis
for siRNA-treated cells). For this analysis, as shown in Supplementary
Fig. S5A, control (scramble), PKCα, δ or ε-knockdown cells were deter-
mined as positive cells (blue), in which n-ERGICwere dispersed, or neg-
ative cells (pink), in which n-ERGIC were normal. By using the method,
we found that dispersed n-ERGIC were observed in ~95% of PKCδ-
knockdown cells, while that observed less in ~30% of control cells or in
~26% of PKCα-knockdown cells (Supplementary Fig. S5B, C).
ERGIC53 is not restricted to ERGIC but rather continuously recy-
cles between the ER, ERGIC, and the Golgi apparatus. So the possibility
exists that we are merely observing the differential effects of rottlerin
treatment or PKCδ knockdown upon the distribution of ERGIC53 in
one of the compartments of the recycling pathway. To resolve this
issue, we ﬁrst examined the localization of two other ERGIC markers
by immunoﬂuorescence microscopy: an integral membrane protein,
Yip1A, and a peripheral membrane protein, Rab2. Recently, we
found that Yip1A, which is a four- or ﬁve-span membrane protein,
localizes to the ERGIC and is involved in Rab6-dependent retrograde
transport from the Golgi to the ER [8]. Rab2 is a cytosolic small GTPase
a fraction of which has been found to be associated with the perinuc-
lear ERGIC [37]. Immunoﬂuorescence microscopy using anti-Yip1A or
anti-Rab2 antibody revealed that the n-ERGIC/cis-Golgi structure in
PKCδ-knockdown cells was dispersed compared to that in the control
(scrambled siRNA) cells (Supplementary Fig. S6A, B). The extent of
this dispersion was also estimated by the same method described in
the Materials and methods. Based on Yip1A staining, the percent of
cells with a dispersed ERGIC in PKCδ-knockdown cells was about 59%
compared to 27% in the control cells. Based on Rab2 staining, the
percent of cells with a dispersed ERGIC in PKCδ-knockdown cells was
about 53% compared to 31% of the control cells (Supplementary Fig.
S6A, B). These results suggest that the n-ERGIC/cis-Golgi is substantially
disrupted by PKCδ knockdown. The similar experiment was performed
in DMSO or rottlerin-treated cells (Supplementary Fig. S6A, B).
Next, we investigated the effect of PKCδ knockdown on the integrity
of n-ERGIC/cis-Golgi structures using non-recycling cargo protein, GFP-
VSVGts045. The protein is known to be transported from the ER to the
Golgi apparatus via the perinuclear and peripheral ERGIC (n/ph-ERGIC)
in a temperature-dependent manner. At 15 °C, transport of VSVG
proteins is initiated from the ER to the Golgi, but the protein accumu-
lates in the n/ph-ERGIC [9]. GFP-VSVGts045 was expressed in HeLa
cells at 39 °C for 24 h, and then the cells were treated with 50 μM
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Fig. 3. PMA can restore the dispersion of the n-ERGIC/cis-Golgi but not the inhibition of VSVG or CtxB transports in the presence of rottlerin. (A) HeLa cells were treated with DMSO
or 20 μM rottlerin for 90 min, and then incubated with DMSO or 200 nM PMA for 60 min. The cells were ﬁxed and immunostained with anti-ERGIC53 and anti-GM130 antibodies.
Scale bars: 10 μm. (B) The graph shows the average percentage of the cells with the n-ERGIC/cis-Golgi dispersed by more than 10 μm. Values represent the means±s.d.; n=100,
***Pb0.0005, N.S. P>0.05 (Student's t-test). (C) HeLa cells were transfected with GFP-VSVGts045 plasmid and incubated at 39 °C for 24 h. The cells were incubated with DMSO or
6 μM rottlerin for 90 min, and then with DMSO or 200 nM PMA for 60 min at 39 °C. Then the cells were transferred from 39 °C to 32 °C to induce the transport of VSVG from the ER,
and incubated for 60 min. The graph shows the mean percentage of cells (±s.d.), in which VSVG was localized to the plasma membrane (PM) n=100. ***Pb0.0005, N.S. P>0.05
(Student's t-test). (D) HeLa cells were treated with DMSO, 6 μM rottlerin, 6 μM rottlerin and 200 nM PMA, or 200 nM PMA for 90 min. Alexa488-conjugated CtxB was bound to the
plasma membrane on ice, and was internalized by incubation at 37 °C for 6 h in the presence of the reagents. The graph shows the mean percentage of cells (±s.d.), in which CtxB
was localized to the ER. n=100. *Pb0.05, **Pb0.005, N.S. P>0.05 (Student's t-test).
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synthesis of VSVG protein. After incubation, the cells were further incu-
bated at 15 °C for 2 h to accumulate GFP-VSVGts045 in the n/ph-ERGIC
and then the cells were subjected to immunoﬂuorescence microscopy.
As shown in Supplementary Fig. S6C, the n-ERGIC/cis-Golgi with atypical compact shape remained within the perinuclear region of the
control cells but was dispersed in the PKCδ-knockdown cells. The
graph in Supplementary Fig. S6C shows that the percent of cells with
a dispersed n-ERGIC/cis-Golgi was about 53% in PKCδ-knockdown
cells compared to 31% in the control cells. This result indicates that
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Fig. 4. PKCδ regulates the morphology of the n-ERGIC/cis-Golgi. HeLa cells were transfected with a scrambled siRNA or a siRNA targeted to PKCδ. (A) After 72 h, the cells were im-
munostained with anti-ERGIC53 and anti-GM130 antibodies. Scale bars: 10 μm. (B) The cells were lysed 72 h after siRNA transfection, and analyzed byWestern blot using anti-PKCδ
or anti-GAPDH antibodies. (C) The graph shows the average percentage of the cells with the n-ERGIC/cis-Golgi dispersed by more than 10 μm. Values represent the means±s.d.;
n=100, ***Pb0.0005 (Student's t-test).
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structures. In addition, a ﬁne structural observation by immuno-EMwas
performed for the GFP-VSVGts045 plasmid transfected samples de-
scribed above to examine whether n-ERGIC/cis-Golgi was actually
dispersed in PKCδ-knockdown cells. As shown in Fig. 5, a typical vesicu-
lar/tubular membrane structures, probably the n-ERGIC, labeled with
colloidal gold against anti-GFP antibody were observed adjacent to the
nuclear in control cells. In contrast, GFP-VSVGts045 was found through-
out cytoplasm in PKCδ-knockdown cells (Fig. 5), while a typical cisternae
of the Golgi remained almost intact in the vicinity of nucleus (indicated
by G in Fig. 5). Taken together with the ﬁnding that PKCδ knockdown
had no effect on anterograde transport of VSVG (as described below),
PKCδ knockdown clearly appears to induce the dispersion of perinuclear
ERGIC structures rather than perturbation of the recycling of ERGIC53.
3.5. PKCδ knockdownhas no effect on anterograde and retrograde transports
via the Golgi
We examined the effect of PKCδ knockdown on the anterograde
transport of VSVG and the retrograde transport of CtxB. Interestingly,
the kinetics of both VSVG and CtxB transport in the PKCδ-knockdown
cells were indistinguishable from those in the control cells. As shown
in Fig. 6, the extent of VSVG transport in PKCδ-knockdown cells was
identical to that in control cells as evidenced by both morphometric
analysis (Fig. 6A) and resistance of VSVG to endo-H (Fig. 6B). In addi-
tion, PKCδ knockdown did not delay the retrograde transport of CtxB
from cell surface to the ER via the Golgi (Fig. 6C). Taken together,knockdown of PKCδ inhibits neither the anterograde transport of
VSVG nor the retrograde transport of CtxB.3.6. PKCε regulates n-ERGIC/cis-Golgi morphology, but not anterograde
and retrograde transports via the Golgi
Soltoff [36] reported that rottlerin could block the activity of kinases
other than PKCδ. To test the possible involvement of other members of
the PKC family in ERGIC structure, we performed gene silencing of the
classical PKC family proteins, PKC α, β, and γ, and a novel PKC family
protein, PKCε, by RNAi. 72 h after transfection with siRNA against
PKCα, β, γ, or ε, the cells were ﬁxed and immunostained with anti-
bodies against ERGIC53 and GM130. No change of n-ERGIC/cis-Golgi
morphology was detected in PKCα, β, or γ-knockdown cells (Supple-
mentary Fig. S7). In contrast, we observed dispersion of the n-ERGIC/
cis-Golgi in PKCε-knockdown cells (Fig. 7A). The expression of PKCε in
PKCε-knockdown cells was reduced to ~10% of control (Scramble)
cells (Fig. 7B). Morphometric analysis revealed that PKCε knockdown
increased the percentage of cells with a dispersed n-ERGIC to ~60%
(Fig. 7C). The effect of PKCε knockdown was also conﬁrmed by AUTO-
MORPH (si) as described above (Supplementary Fig. S5).We also inves-
tigated the anterograde transport of VSVG and the retrograde transport
of CtxB in PKCε-knockdown cells and conﬁrmed that gene silencing of
PKCε did not affect VSVG and CtxB transports (Fig. 7D, E), as was the
case following knockdown of PKCδ. In addition, we examined the effect
of double knockdown of PKCδ and ε on themorphology of the n-ERGIC/
Fig. 5. Immuno-electron microscopic observation of GFP-VSVGts045 in PKCδ-knockdown cells. Control or PKCδ-knockdown HeLa cells were transfected with plasmid encoding GFP-
VSVGts045. After incubation at 39 °C for 24 h, the cells were treated with 50 μM cycloheximide at 39 °C for 30 min, and were incubated at 15 °C for 2 h. The cells were analyzed by
immunoelectron microscopy by using a pre-embedding gold enhancement method. Right images show higher magniﬁcation of the rectangle in left ﬁgures. The cisternal Golgi
stacks were indicated by alphabet G. Bar=2 or 1 μm.
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reduced to approximately 69 or 56% of the normal level by gene silencing
of PKCδ or ε (Supplementary Fig. S8B, C). As shown in Supplementary Fig.
S8, the percentage of cells with a dispersed n-ERGIC/cis-Golgi in double
knockdown cells was similar to that of cells, in which each kinase was
knocked down separately (Supplementary Fig. S8A, D; compared to
Figs. 4C, 7C). The kinetics of VSVG and CtxB transport between the two
types of knockdown cells appeared to be similar (Supplementary Fig.
S8E, and data not shown). These results indicate that the effect of knock-
downof each kinase on ERGICmorphology andVSVG andCtxB transports
is not additive, indicating that PKCδ and εmediate these effectswithin the
context of a single signaling pathway.
Rottlerin has been reported to inhibit the activity of eukaryotic elon-
gation factor 2 kinase (CaM kinase III) and mitogen-activated protein
kinase-activated protein kinase 2 (MAPKAP-K2) [36]. However, speciﬁc
inhibitors of these kinases had no effect upon either the morphology of
the n-ERGIC/cis-Golgi or VSVG transport (Supplementary Fig. S9).3.7. Uncoupling ofmitochondrial membrane potential causes the dispersion
of the n-ERGIC/cis-Golgi and the inhibition of anterograde and retrograde
transports via the Golgi
Rottlerin is utilized as a PKCδ-speciﬁc inhibitor, which is ques-
tioned since rottlerin acts directly to uncouple mitochondria in a
PKC-independent manner and facilitates a reduction in the levels of
intracellular ATP [38]. To conﬁrm the decrease in mitochondrial mem-
brane potential by rottlerin, we used tetramethyl rhodamine methylester (TMRM) as aﬂuorescent probe tomonitor themembrane potential.
HeLa cells were treated with 6 μM rottlerin or 10 μM FCCP, a mitochon-
drial protonophore, for 90 min, then further incubated with 30 nM
TMRM for 30 min. The cells were observed by confocal microscopy. We
found that both rottlerin and FCCP reduced the ﬂuorescence of TMRM
(Fig. 8A). Furthermore, we measured the total ﬂuorescence of TMRM in
cells treated with DMSO, rottlerin, or FCCP using ﬂow cytometry. As
shown in Fig. 8B, the TMRM ﬂuorescence in rottlerin- or FCCP-treated
cells was decreased to ~6% or ~13% respectively of the value observed
in control cells. These results demonstrate an uncoupling effect on the
mitochondrial membrane by rottlerin, which is consistent with previous
reports [39–41]. We also measured the total amount of intracellular ATP
in rottlerin- or FCCP-treated cells by a luciferin/luciferase assay (see
Materials and methods), because of the close relationship between the
mitochondrial membrane potential and ATP synthesis. Rottlerin or
FCCP reduced the amount of total intracellular ATP to 83% or 87%, respec-
tively, of the value observed in DMSO treated cells (Supplementary Fig.
S10). Taken together, these ﬁndings indicate that rottlerin induces mito-
chondrial uncoupling.
We next examined whether the decrease in the mitochondrial
membrane potential by FCCP inhibited anterograde or retrograde
transports and whether it induced any morphological changes in
the n-ERGIC/cis-Golgi. We ﬁrst investigated the effect of FCCP on
anterograde transport of VSVG. 15 min after release from tempera-
ture block, the percentage of cells in which VSVG had accumulated
at the Golgi, was ~40% in FCCP-treated cells, compared to ~95% in
control cells (Fig. 8C). In addition, VSVG had reached the plasma
membrane after 90 min in ~100% of control cells, but in only ~50%
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Fig. 6. Transport assay for VSVG and CtxB in PKCδ-knockdown cells. (A) Kinetics of GFP-VSVGts045 transport in control (Scramble) or PKCδ-knockdown cells. The graph shows the
mean percentage of cells (±s.d.), in which GFP-VSVGts045 was localized to the ER, to the Golgi or to the plasma membrane (PM) n=100. (B) Biochemical transport assay for GFP-
VSVGts045 using endo-H. 48 h after siRNA transfection, the cells were transfected with GFP-VSVGts045 plasmid and incubated at 39 °C for 24 h. Then the cells were transferred
from 39 °C to 32 °C to induce the transport of VSVG from the ER, and incubated for 60 min. The cells were lysed and incubated with endo-H. The proteins were separated by
SDS-PAGE and immunoblotted with anti-GFP and anti-GAPDH antibodies. (C) Kinetics of CtxB transport in control (Scramble) or PKCδ-knockdown cells. The graph shows the
mean percentage of cells (±s.d.), in which CtxB was localized to the plasma membrane (PM), to the Golgi or to the ER n=100.
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delayed the retrograde transport of CtxB (Fig. 8D). The result is that 0.5 h
after CtxB was endocytosed, CtxB reached the Golgi in 77% of control
cells, while in 35% of FCCP-treated cells. In 6 h incubation, CtxB was
transported to the ER in 70% of control cells, whereas in 50% of FCCP-
treated cells. We next performed immunoﬂuorescence of ERGIC53 and
GM130 in FCCP-treated cells, and found that FCCP facilitated the disper-
sion of the n-ERGIC/cis-Golgi (Fig. 9A). Morphometric analysis revealed
that ~60% of FCCP-treated cells exhibited dispersion of the n-ERGIC/cis-
Golgi (Fig. 9B). These results indicated that the decrease inmitochondrial
membranepotential perturbedboth ERGICmorphology and anterograde
and retrograde transports via the Golgi.
To test whether the FCCP-mediated changes in n-ERGIC/cis-Golgi
morphology was dependent upon PKC, we examined the effect of
PMA on n-ERGIC/cis-Golgi structure in FCCP-treated cells. HeLa cells
were treated with FCCP in the presence or the absence of 200 nM
PMA for 90 min, and thenwere immunostainedwith antibodies against
ERGIC53 and GM130. As shown in Fig. 9A and B, PMA treatment
restores n-ERGIC/cis-Golgi structure. We found that the percentage of
cells with a dispersed ERGIC was decreased from 60% in FCCP-treated
cells to 34% by treatment with 200 nM (Fig. 9B). Consequently, these
results suggest that PKC is also involved in FCCP-induced dispersion of
the n-ERGIC/cis-Golgi. Furthermore, we found that mitochondrial
membrane potential in PKCδ-knockdown cells was indistinguishablefrom that in control cells (data not shown), indicating that PKCδ had
no effect on the mitochondrial function. These results suggested that
PKCδ was involved in the dispersion of the n-ERGIC/cis-Golgi, without
mediating the mitochondrial dysfunction.
4. Discussion
We screened 80 kinase inhibitors and found that rottlerin, a PKCδ
inhibitor, and AG1478, an EGFRK inhibitor, induced the dispersion of
the n-ERGIC/cis-Golgi into the cytoplasm in the form of punctate
structures. AG1478-induced disruption of the n-ERGIC/cis-Golgi is
consistent with a report by Heling Pan et al. [27], who demonstrated
that AG1478 inhibited the function of GBF1, a nucleotide exchange
factor for Arf, resulting in the fragmentation of the cis-Golgi and the
ERGIC. Therefore, in this study we focused our efforts on the effect
of rottlerin on the morphology of the n-ERGIC/cis-Golgi.
4.1. Regulation of ERGIC or Golgi morphology by PKCδ and ε
We found that rottlerin affected the structure of the n-ERGIC/cis-
Golgi and gave rise to modest changes in the morphology of the
medial- and trans-Golgi (Fig. 1A and Supplementary Fig. S1A). As
shown in Fig. 1A, ERGIC53 and GM130 were observed as cytoplasmic
punctate structures in rottlerin-treated cells. On the other hand, the
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Fig. 7. PKCε regulates the morphology of the n-ERGIC/cis-Golgi but not VSVG and CtxB transports. HeLa cells were transfected with a scrambled siRNA or a siRNA targeted to PKCε. (A)
After 72 h, the cells were immunostained with anti-ERGIC53 and anti-GM130 antibodies. Scale bars: 10 μm. (B) The cells were lysed 72 h after siRNA transfection, and analyzed byWest-
ern blot using anti-PKCε or anti-GAPDH antibodies. (C) The graph shows the average percentage of the cells with the n-ERGIC/cis-Golgi dispersed by more than 10 μm. Values represent
themeans±s.d.; n=100, ***Pb0.0005 (Student's t-test). (D) Kinetics of GFP-VSVGts045 transport in control (Scramble) or PKCε-knockdown cells. The graph shows themeanpercentage
of cells (±s.d.), in which GFP-VSVGts045 was localized to the ER, to the Golgi or to the plasma membrane (PM) n=100. (E) Kinetics of CtxB transport in control (Scramble) or PKCε-
knockdown cells. The graph shows the mean percentage of cells (±s.d.), in which CtxB was localized to the plasma membrane (PM), to the Golgi or to the ER n=100.
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disassembled partially, but did not disperse into punctate structures.
Similar changes in ERGIC and Golgi morphology were detected in
PKCδ- or ε-knockdown cells (Fig. 4A, 7A, Supplementary Fig. S1C).
To examine the ﬁne structure of the ERGIC and the Golgi, we per-
formed conventional EM observation and found that the n-ERGIC
was disrupted by rottlerin treatment or PKCδ knockdown, while the
Golgi stacks were maintained (Fig. 5, Supplementary Fig. S1B). In ad-
dition, PMA, an activator of PKC, restored n-ERGIC/cis-Golgi morphol-
ogy in rottlerin- or FCCP-treated cells (Figs. 3A, B and 9A, B).
Therefore, these results suggest that PKCδ or ε is the predominant ki-
nases that regulate the morphology of the n-ERGIC/cis-Golgi. Interest-
ingly, the results of the double knockdown experiments shown in
Supplementary Fig. S8 suggest that these kinases regulate changesin n-ERGIC/cis-Golgi morphology as components of a single signaling
pathway. The relative position of these kinases within this pathway
remains to be determined.
Since phosphorylation of PKCδ at Thr505 is reported to be associated
with increased kinase activity [35], we performed Western blot using
the phosphospeciﬁc antibody against PKCδ (Thr505). As shown in Sup-
plementary Fig. S2D, E, Thr505 phosphorylation was decreased to only
~76% in rottlerin treated cells. The small decrease in Thr505 phosphory-
lation in response to rottlerin treatmentwas surprising. As PKCδ is active
even when Thr505 is unphosphorylated [35], the rottlerin-mediated
decrease in PKCδ activity might not be correlated with its phosphoryla-
tion status at Thr505. In this study, we further performed knockdown of
PKCδ using RNAi, and we veriﬁed the involvement of PKCδ in the n-
ERGIC/cis-Golgi dispersion (Fig. 4). So a functional modiﬁcation of
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Fig. 8. FCCP recapitulates the rottlerin-induced inhibition of VSVG and CtxB transports. (A) The cells were treated with 6 μM rottlerin or 10 μM FCCP, and then incubated with 30 nM
TMRM for 30 min to visualize the mitochondrial membrane potential. Scale bars: 10 μM. (B) Rottlerin or FCCP-treated cells were incubated with TMRM as described in experiment
A, and then trypsinized. The ﬂuorescence intensity per cell was measured by ﬂow cytometry. The graph shows the mean percentage of the ﬂuorescence intensity (±s.d.).
***Pb0.0005 (Student's t-test). (C) Kinetics of GFP-VSVGts045 transport in control or FCCP-treated cells. The graph shows the mean percentage of the cells (±s.d.), in which
GFP-VSVGts045 was localized to the ER, to the Golgi or to the plasma membrane (PM) n=100. (D) Kinetics of CtxB transport in control or FCCP-treated cells. The graph shows
the mean percentage of cells (±s.d.), in which CtxB was localized to the plasma membrane (PM), to the Golgi or to the ER n=100.
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the n-ERGIC/cis-Golgi structure.
Both the maintenance of Golgi morphology [42] and anterograde
transport from the ER are largely dependent upon microtubule integrity
[9,10]. Therefore, we examined the effects of rottlerin on microtubules
by immunoﬂuorescence using an anti-βtubulin antibody. As shown in
Supplementary Fig. S11, the structures and orientation of the microtu-
bules remained intact in cells treatedwith rottlerin. Therefore, loss ofmi-
crotubule integrity is not a likely cause of rottlerin-induced perturbation
of the Golgi structure and VSVG transport.
Our bioinformatics approach revealed that c-Met and p23 interact
with or are phosphorylated by both PKCδ and ε. C-Met, is a trans-
membrane protein that localizes to the plasma membrane and is a re-
ceptor for of hepatocyte growth factor (HGF). Upon treatment withHGF, the c-Met/HGF complex is internalized and transported to the
perinuclear compartment, including the Golgi. Kermorgan et al. [43]
reported that PKC promotes the trafﬁc of c-Met from early endosomes
to a perinuclear compartment. Another candidate factor acting down-
stream of PKCδ, p23, belongs to the p24 family, and plays a role in se-
lective ER export of GPI-anchored proteins [44]. Wang et al. [45]
reported that PKCδ interacts with p23, and that disruption of this in-
teraction leads to an enhanced apoptotic response, possibly due to
the regulation of PKCδ localization by p23. Interestingly, Rojo et al.
[46] observed fragmentation of the Golgi apparatus without affecting
anterograde (VSVG) or retrograde (B subunit of verotoxin) transport
following removal of endogenous p23 from the cis-Golgi by ectopic
overexpression of p23. Therefore, it is possible that PKCδ stimulates
the function and/or the Golgi-association of p23, and that rottlerin-
AB
Fig. 9. PMA restores FCCP-induced dispersion of the n-ERGIC/cis-Golgi. (A) HeLa cells were treated with 10 μM FCCP in the presence or absence of 200 nM PMA for 90 min. Then the
cells were immunostained with anti-ERGIC53 and GM130 antibodies. Scale bars: 10 μm. (B) The graph shows the average percentage of the cells with the n-ERGIC/cis-Golgi dis-
persed by more than 10 μm. Values represent the means±s.d.; n=100, *Pb0.05, (Student's t-test).
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p23 through inactivation of PKCδ. We are currently testing this
hypothesis.
4.2. Rottlerin might inhibit the anterograde and retrograde transports
through mitochondrial dysfunction
We found that anterograde transport of VSVG and retrograde trans-
port of CtxB were inhibited in rottlerin-treated cells (Fig. 2B, C, F, G), but
not in PKCδ- or ε-knockdown cells (Figs. 6, 7D, E). This ﬁnding suggestedthat rottlerin is not a speciﬁc inhibitor for PKCδ. In fact, rottlerin has been
reported to inhibit several kinases other than PKCδ and also to uncouple
themitochondrialmembranepotential [36]. Amongst a variety of effects
of rottlerin, we show that depolarization of the mitochondrial mem-
brane potential was the major factor underlying rottlerin-mediated
inhibition of anterograde and retrograde transports via the Golgi. As
shown in Figs. 8, 9, treatment with FCCP, an uncoupler of mitochondrial
oxidative phosphorylation, caused the n-ERGIC/cis-Golgi to disperse
into punctate structures and inhibited VSVG and CtxB transport, as
was observed following rottlerin treatment. An important next question
874 T. Sugawara et al. / Biochimica et Biophysica Acta 1823 (2012) 861–875then is how mitochondrial depolarization affects anterograde transport
from the ER and the retrograde transport from the cell surface. We
believe that a decrease in intracellular ATP caused by rottlerin or FCCP
leads to the block in vesicular transports. There have been several pio-
neering reports of the effect of ATP-depletion by FCCP (or its analog
CCCP) on ER–Golgi transport [47–49]. They found that the transport of
virus membrane glycoproteins is sensitive to energy depletion by FCCP
in cells, as is the transport of secretory glycoproteins both in regulated
andnonregulated cells. Based on their studies of IgM secretion in plasma
cells, Tartakoff and colleagues have suggested that the inhibition of en-
ergy production by CCCP-treatment inhibited the exit of IgM molecules
from the ER. Moreover, Kääriäinen and colleagues [50] also reported
that FCCP inhibited the appearance of temperature-sensitive mutants
of Semliki Forest virus (SFV) and Sindbis virus (SIN), virus membrane
glycoproteins, at the cell surface. They also suggested that the inhibition
by FCCPmight be due to the inhibition of the fusion of secretary vesicles
containing glycoproteins with the target membrane, an event that re-
quires energy from ATP. These ﬁndings suggest that ATP production
from mitochondria plays a crucial role in various elementary processes
of membrane trafﬁcking studied in this paper. As shown in Supplemen-
tary Fig. S10, the total amount of intracellular ATP in rottlerin-treated
cells was decreased to ~83% of that observed in control cells. Vesicular
transport requires ATP at multiple steps, such as vesicle formation,
vesicle transfer by motor proteins, and vesicle fusion etc. Although the
requisite quantity of ATP for vesicular transport in the cells is unknown,
it seems reasonable that reduced ATP availability could inhibit the pro-
gression of anterograde and retrograde transport. It is noteworthy that
the reduction in VSVG transport was more modest in FCCP-treated
cells (Fig. 8C, 15 min: Golgi ~40%) than in rottlerin-treated cells
(Fig. 2C, 15 min: Golgi ~10%), indicating that other factors contribute
to the inhibition of ER-to-Golgi transport by rottlerin.
In this study, RNAi experiments revealed that knockdown of PKCδ
did not inhibit the retrograde transport of CtxB (Fig. 6C). In contrast,
Shiga toxin (Stx) required PKCδ for its retrograde transport. Torgersen
et al. [51] demonstrated that binding of Stx to cells stimulates PKCδ,
which selectively regulated the endosome-to-Golgi transport of Stx.
Therefore, Stx and CtxB might be transported from endosomes to the
Golgi via different routes. This possibility is supported by the study of
Bujny et al. [52], who showed that Stx transport from the endosome
to the Golgi was largely dependent on sorting nexin-1, whereas the
transport of CtxB was less dependent.
4.3. Relationship between ERGIC morphology and the function
We found that ERGIC53-positive and GM130-positive structures
are similarly distributed within the cytoplasm of rottlerin-treated or
PKCδ-knockdown cells. This might be because GM130 is present in
the late intermediate compartment (IC), which might be a part of
the perinuclear ERGIC (n-ERGIC), and recycles between the IC
compartment and the cis-Golgi. It has been reported that the Rab1-
positive IC around the centrosome might be involved in a direct func-
tional connection with the endosomal system [53]. This evidently
contributes to the unconventional transport of proteins, for example
the cystic ﬁbrosis transmembrane conductance regulator, from the
ER to the cell surface. So, it is possible that VSVG is transported
from the ER to the cell surface via the IC around the centrosome,
but not via the Golgi, which might contribute to the similar level of
transport of VSVG in PKCδ-knockdown and control cells (Fig. 6A, B).
However, this scenario is unlikely since biochemical analysis of endo-H
resistance of cell-surface VSVG revealed that it was processed normally
in the Golgi in PKCδ-knockdown cells (Fig. 6B). Morphological analysis
using ﬂuorescence microscopy also indicated that medial- or trans-
Golgi morphology in PKCδ-knockdown cells was just disassembled in
the perinuclear region (see in detail Supplementary Fig. S1C) although
the n-ERGIC/cis-Golgi structures were dispersed throughout the cyto-
plasm as dotted structures. Furthermore, we conﬁrmed by electronmicroscopy that stacks of the Golgi apparatus were maintained in
PKCδ-knockdown cells (Fig. 5). Collectively, these results indicate that
the Golgi apparatus remained nearly intact and that VSVG could be
transported normally from the ER to the cell surface via the Golgi in
PKCδ-knockdown cells.
Interestingly, the late IC is believed to undergo homotypic fusion
and to establish tubular connections between themselves and with
the Golgi [54]. A tether protein complex, p115-Rab1-GM130-GRASP65
tether, is reported to be involved in the docking of ICs with one another
so as to form fused structures or tubular connections [55]. Collectively,
one possibility is that rottlerin treatment and PKCδ-knockdown might
inhibit this homotypic fusion and tubular organization by inhibiting
the formation of a tether protein complex, leading to the dispersal of
n-ERGIC structures throughout the cytoplasm.
In this study, we revealed that disruption of ERGIC structure by
knockdown of PKCδ or ε had no effect on the anterograde transport of
VSVG from the ER to the plasma membrane. Others reported that heat
shock induced the disruption of the n-ERGIC, but that it did not inhibit
anterograde transport from the ER to theGolgi [56]. These results suggest
the possibility that maintenance of ERGIC structure is not required for
ER-to-Golgi transport. This ﬁnding raises the question of the signiﬁcance
of the maintenance of ERGIC structure. Recently, several researchers
demonstrated that the ERGIC also contributes to the concentration, fold-
ing, and quality control of newly synthesized proteins [57]. Bendayan
[58] showed that amylase and chymotrypsinogen in pancreatic acinar
cells are concentrated not in COPII-coated vesicles but at the ERGIC,
and this appears to result from exclusion of these proteins from retro-
grade COPI vesicles [32]. Increasing evidence indicates that the ERGIC is
also involved in conformation based quality control of proteins and,
possibly, protein folding. A proteomic approach to search for proteins
cycling in the early secretory pathway revealed that several chaperones
are enriched in ERGIC membranes isolated from brefeldin A-treated
cells [59]. Therefore, incompletely folded proteins that escape the ER
quality control stage because of system overload or failed recognition
can be caught by a subsequent checkpoint in the ERGIC. Themorphology
of the ERGIC might be important for these biological processes and this
remains to be elucidated in the future.
Supplementary materials related to this article can be found online
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